Korro Bio (NASDAQ:KRRO) Director Sells $130,149.08 in Stock

Posted by George Bondi on Jul 10th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Francois Formela sold 9,323 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $13.96, for a total transaction of $130,149.08. Following the transaction, the director directly owned 146,305 shares in the company, valued at $2,042,417.80. This represents a 5.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jean Francois Formela also recently made the following trade(s):

On Thursday, July 2nd, Jean Francois Formela sold 100,700 shares of Korro Bio stock. The shares were sold at an average price of $14.03, for a total value of $1,412,821.00.
On Wednesday, June 24th, Jean Francois Formela sold 48,438 shares of Korro Bio stock. The shares were sold at an average price of $14.61, for a total value of $707,679.18.
On Tuesday, June 23rd, Jean Francois Formela sold 119,005 shares of Korro Bio stock. The stock was sold at an average price of $14.25, for a total value of $1,695,821.25.
On Monday, June 22nd, Jean Francois Formela sold 3,962 shares of Korro Bio stock. The stock was sold at an average price of $13.95, for a total value of $55,269.90.
On Thursday, May 28th, Jean Francois Formela sold 2,860 shares of Korro Bio stock. The shares were sold at an average price of $13.95, for a total value of $39,897.00.

Korro Bio Stock Performance

NASDAQ:KRRO opened at $14.30 on Friday. Korro Bio, Inc. has a fifty-two week low of $5.20 and a fifty-two week high of $55.89. The company has a market cap of $206.21 million, a price-to-earnings ratio of -1.23 and a beta of 3.00. The stock has a fifty day moving average price of $12.22 and a 200-day moving average price of $11.59.

Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. Research analysts predict that Korro Bio, Inc. will post -5.36 EPS for the current fiscal year.

Institutional Trading of Korro Bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in Korro Bio during the 3rd quarter worth about $39,000. Wells Fargo & Company MN raised its position in shares of Korro Bio by 45.5% during the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after acquiring an additional 2,352 shares during the last quarter. Guggenheim Capital LLC bought a new position in shares of Korro Bio during the fourth quarter worth about $84,000. Jain Global LLC acquired a new position in shares of Korro Bio in the fourth quarter worth approximately $85,000. Finally, Deutsche Bank AG boosted its holdings in Korro Bio by 241.9% in the fourth quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock valued at $102,000 after acquiring an additional 9,027 shares during the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KRRO has been the subject of several research analyst reports. Raymond James Financial raised Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research note on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a report on Monday. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Lifesci Capital upgraded shares of Korro Bio to a “strong-buy” rating in a report on Friday, May 29th. Finally, Citigroup initiated coverage on Korro Bio in a research note on Monday, May 18th. They issued a “buy” rating and a $21.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.71.

Read Our Latest Stock Report on KRRO

About Korro Bio

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.